Empagliflozin in Patients with Chronic Kidney Disease.
null nullWilliam G HerringtonNatalie StaplinChristoph WannerJennifer B GreenSibylle J HauskeJonathan R EmbersonDavid PreissParminder JudgeKaitlin J MayneSarah Y A NgEmily SammonsDoreen ZhuMichael HillWill StevensKarl WallendszusSusanne BrennerAlfred K CheungZhi-Hong LiuJing LiLai Seong HooiWen LiuTakashi KadowakiMasaomi NangakuAdeera LevinDavid CherneyAldo P MaggioniRoberto PontremoliRajat DeoShinya GotoXavier RosselloKatherine R TuttleDominik SteublMichaela PetriniDan MasseyJens EilbrachtMartina BrueckmannMartin J LandrayColin BaigentRichard HaynesPublished in: The New England journal of medicine (2022)
Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo. (Funded by Boehringer Ingelheim and others; EMPA-KIDNEY ClinicalTrials.gov number, NCT03594110; EudraCT number, 2017-002971-24.).